CDMO Appoints Business Development Managers to Further Revenues Growth in Europe
Aesica has appointed Sven Thomas and David Ross as business development managers. Their appointment is the next phase in the company’s international drive to increase sales from its integrated API, formulation development and manufacturing services and they will be responsible for ensuring potential customers are clearly aware of how the company can support their manufacturing and development needs.
Under the new structure, Ross will focus on the UK, Ireland and Scandinavia, whilst Thomas will handle Central and Eastern Europe, with a strong emphasis on expanding the level of business from Germany and the growing economies in Eastern Europe. In combination, three business development managers — Nicholas Micheaud, who has responsibility for South Western Europe, Ross and Thomas — report to Jeremy Drummond, Sales Director. Thomas brings a breadth of pharmaceutical manufacturing expertise to the task in hand, having previously worked for UCB, whilst Ross brings wide ranging experience in contract research and contract manufacturing with Patheon, Catalant and Ipsen.
Thomas commented: “I am delighted to take on my new position at Aesica and to play a key role in driving forward our services in the German market as well as Eastern Europe. Indeed, the fact that we have site facilities geographically situated in Monheim and Zwickau, as well as in Italy and the UK, ensures that Aesica is well-situated to deliver reliable services to customers from all of Europe.”
“Moreover, we have a strong pedigree in Germany with over thirty years’ manufacturing, working on established UCB and Schwarz products at our Zwickau and Monheim sites. We provide a bespoke individualised approach to client servicing and have the flexibility to cater for what are often multiple formulated product needs of each customer.”
Ross remarked: “I very much look forward to playing a key regional role in driving new business across the UK, Ireland and Scandinavia. The integrated nature, scale and range of our service offering and our track record of transferring in new technologies stand us out in the highly competitive CDMO marketplace.”
Aesica Pharmaceuticals Ltd, +44 191 218 1960, info@aesica-pharma.com,